Popular search terms:
Search Results
98 results found-
Welcome to CSL Behring Canada. Our portfolio of innovative medicines includes a wide range of recombinant and plasma-derived products for treating bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as hereditary angioedema and Alpha-1 Antitrypsin Deficiency.
https://www.cslbehring.ca/news/2026/csl-canada-announces-first-canadian-patient-receives-hemgenix -
More than 100 years ago, CSL was formed to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives.
https://www.cslbehring.ca/our-company -
Our Values Patient Focus Integrity Innovation Superior Performance Collaboration
https://www.cslbehring.ca/-/media/cslb-canada/documents/csl-statement-on-modern-slavery_2025.pdf -
CSL continues to provide medicines to patients around the world.
https://www.cslbehring.ca/news/2020/covid-19-update -
CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
https://www.cslbehring.ca/news/2020/csl-and-sab-therapeutics -
CSL Behring and SAB Therapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic
https://www.cslbehring.ca/fr-fr/nouvelles/2020/csl-and-sab-therapeutics -
January is National Mentoring Month, but some seek STEM-focused learning year-round.
https://www.cslbehring.ca/news/2018/20180130-mentoring-month -
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
https://www.cslbehring.ca/news/2020/global-plasma-leaders-collaborate -
Bienvenue chez CSL Behring Canada. Notre panoplie de médicaments innovants comprend une large gamme de produits recombinants et dérivés du plasma pour le traitement des troubles de la coagulation, des déficits immunitaires et de la polyneuropathie démyélinisante inflammatoire chronique, ainsi que l'angio-œdème héréditaire et le déficit en alpha-1 antitrypsine.
https://www.cslbehring.ca/fr-fr/nouvelles/2026/csl-canada-announces-first-canadian-patient-receives-hemgenix -
Nous avons procédé à un ciblage rigoureux des principaux fournisseurs actuels de CSL en vue d'un éventuel programme de collaboration future.
https://www.cslbehring.ca/-/media/cslb-canada/documents/csl-mss_2025_french-translation.pdf